Want to see MBIO full AI Analyst Report?
MBIO Stock Chart & Stats
$1.09
-$0.01(-4.59%)
At close: 4:00 PM EST
$1.09
-$0.01(-4.59%)
Day’s Range― - ―
52-Week Range$0.53 - $3.00
Previous CloseN/A
Volume2.68M
Average Volume (3M)94.14K
Market Cap
$5.61M
Enterprise Value-$10.75M
Total Cash (Recent Filing)$16.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,732,120
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.91
Enterprise Value/Market Cap-1.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda3.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetZero reported debt and a recovery of stockholders’ equity materially reduce solvency risk and interest burden. This improves financial flexibility to fund clinical programs or negotiate collaborations, extending runway and lowering default risk versus prior periods.
Material Reduction In Cash BurnA multi-year decline in operating cash outflow shows improving capital efficiency and disciplined spending. Sustained lower burn reduces near-term financing needs, increasing likelihood cash can support key clinical milestones without immediate dilutive raises.
Focused Advanced Therapy PipelineConcentrated expertise in CAR T and gene therapies targets high unmet medical needs with high barriers to entry. Success would create durable competitive advantages and potential for outsized returns from transformative, long-duration product franchises.
Bears Say
Pre-revenue ProfileWith no product revenue, the company lacks recurring cash inflows to fund operations. Long-term viability therefore depends on future clinical success and external financing, making operational continuity vulnerable to trial setbacks or capital-market conditions.
Ongoing Negative Cash FlowPersistent negative operating and free cash flows mean the business is not self-sustaining. Even with improved burn, continued external funding or partnerships will be required to advance trials, raising dilution and execution risk over the next several quarters.
Limited Operating ScaleA very small team and shrinking asset base constrain internal R&D throughput and commercialization preparation. Mustang will likely rely on external partners or CROs, which can slow timelines, increase costs, and limit direct control over program execution.
Mustang Bio News
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.53 and its highest was $3.00 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Mustang Bio Inc’s market cap is $5.61M.
When is Mustang Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mustang Bio Inc’s earnings last quarter?
Currently, no data Available
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 6,732,120 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Silexion Therapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
8.01% Insiders
1.11% Mutual Funds
0.30% Other Institutional Investors
90.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---